Insider Trading Activity Puma Biotechnology Inc (NYSE:PBYI) – SVP Sold 1,998 shares of Stock

Insider Trading Activity For Puma Biotechnology Inc (NYSE:PBYI)

Richard Paul Bryce , SVP of Puma Biotechnology Inc (NYSE:PBYI) reportedly Sold 1,998 shares of the company’s stock at an average price of 94.48 for a total transaction amount of $188,771.04 SEC Form

Insider Trading History For Puma Biotechnology Inc (NYSE:PBYI)

On 10/18/2012 Adage Capital Partners Gp Llc, Major Shareholder, bought 610,000 with an average share price of $16.00 per share and the total transaction amounting to $9,760,000.00.View SEC Filing

On 10/24/2012 Thomas Malley, Director, bought 10,000 with an average share price of $16.00 per share and the total transaction amounting to $160,000.00.View SEC Filing

On 12/11/2012 Adage Capital Partners Gp Llc, Major Shareholder, bought 140,040 with an average share price of $18.98 per share and the total transaction amounting to $2,657,959.20.View SEC Filing

On 12/12/2012 Adage Capital Partners Gp Llc, Major Shareholder, bought 30,400 with an average share price of $19.00 per share and the total transaction amounting to $577,600.00.View SEC Filing

On 12/18/2012 Adage Capital Partners Gp Llc, Major Shareholder, bought 29,560 with an average share price of $19.00 per share and the total transaction amounting to $561,640.00.View SEC Filing

On 10/9/2013 Adage Capital Partners Gp Llc, major shareholder, bought 140,900 with an average share price of $40.44 per share and the total transaction amounting to $5,697,996.00.View SEC Filing

On 11/5/2013 Adage Capital Partners Gp Llc, major shareholder, bought 280,700 with an average share price of $39.60 per share and the total transaction amounting to $11,115,720.00.View SEC Filing

Analyst Ratings For Puma Biotechnology Inc (NYSE:PBYI)
These are 1 Hold Rating, 7 Buy Ratings .
The current consensus rating for Puma Biotechnology Inc (NYSE:PBYI) is Buy (Score: 2.88) with a consensus target price of $111.13 , a potential (15.94% upside)

Analyst Ratings History For Puma Biotechnology Inc (NYSE:PBYI)

• On 1/5/2016 Berenberg Bank Upgraded rating Hold to Buy
• On 7/18/2017 Credit Suisse Group Reiterated Rating Outperform with a price target of $90.00 to $118.00
• On 7/18/2017 Stifel Nicolaus Reiterated Rating Buy with a price target of $105.00 to $118.00
• On 7/18/2017 Citigroup Inc. Reiterated Rating Buy with a price target of $114.00
• On 7/18/2017 J P Morgan Chase & Co Reiterated Rating Buy
• On 7/17/2017 Royal Bank Of Canada Set Price Target of rating Hold with a price target of $88.00
• On 7/19/2017 Leerink Swann Reiterated Rating Outperform with a price target of $115.00 to $125.00

Recent Trading Activity for Puma Biotechnology Inc (NYSE:PBYI)
Shares of Puma Biotechnology Inc closed the previous trading session at 95.85 up +1.55 1.64% with 1,274,520 shares trading hands.